IBRX News

IBRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Class Action Lawsuit Reminder from Pomerantz LLP for Investors of ImmunityBio, Inc. – IBRX

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA ® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

IBRX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Ready to Announce with Confidence?

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman